Atossa Therapeutics (ATOS) outlined a framework for a pioneering Phase 3 clinical study titled SMART 2.0. The proposed trial would investigate the potential of oral (Z)-endoxifen, a potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition, to significantly reduce interval breast cancer in women identified as high-risk through advanced mammographic screening techniques. The proposed SMART 2.0 study was presented at the American Association for Cancer Research Annual Meeting and represents a future research program and potential partnership opportunity to advance this critical initiative for women at high risk of breast cancer.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATOS:
- Atossa Therapeutics announces issuance of U.S. patent
- Atossa Therapeutics and Nona Biosciences partner in breast cancer antibodies
- Atossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical Progress
- Strategic Advancements and Promising Clinical Data Drive Buy Rating for Atossa Therapeutics
- Atossa Therapeutics Reports 2024 Financial Results and Updates
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue